🚀 VC round data is live in beta, check it out!
TELA Bio Valuation Multiples
Discover revenue and EBITDA valuation multiples for TELA Bio and similar public comparables like Myomo, IMD International Medical, Icecure Medical, European Medical Solutions and more.
TELA Bio Overview
About TELA Bio
TELA Bio Inc a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s anatomy. Its growing product portfolio is purposefully designed to leverage the patient’s natural healing response while minimizing long-term exposure to permanent synthetic materials. The company's OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair.
Founded
2012
HQ
Employees
209
Website
Financials (LTM)
EV
$32M
TELA Bio Financials
TELA Bio reported last 12-month revenue of $82M and negative EBITDA of ($30M).
In the same LTM period, TELA Bio generated $56M in gross profit, ($30M) in EBITDA losses, and had net loss of ($39M).
Revenue (LTM)
TELA Bio P&L
In the most recent fiscal year, TELA Bio reported revenue of $80M and EBITDA of ($31M).
TELA Bio expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $82M | XXX | $80M | XXX | XXX | XXX |
| Gross Profit | $56M | XXX | $54M | XXX | XXX | XXX |
| Gross Margin | 68% | XXX | 68% | XXX | XXX | XXX |
| EBITDA | ($30M) | XXX | ($31M) | XXX | XXX | XXX |
| EBITDA Margin | (37%) | XXX | (38%) | XXX | XXX | XXX |
| EBIT Margin | (40%) | XXX | (42%) | XXX | XXX | XXX |
| Net Profit | ($39M) | XXX | ($39M) | XXX | XXX | XXX |
| Net Margin | (47%) | XXX | (48%) | XXX | XXX | XXX |
| Net Debt | — | — | $5M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
TELA Bio Stock Performance
TELA Bio has current market cap of $27M, and enterprise value of $32M.
Market Cap Evolution
TELA Bio's stock price is $0.60.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $32M | $27M | -2.7% | XXX | XXX | XXX | $-0.87 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialTELA Bio Valuation Multiples
TELA Bio trades at 0.4x EV/Revenue multiple, and (1.1x) EV/EBITDA.
EV / Revenue (LTM)
TELA Bio Financial Valuation Multiples
As of April 11, 2026, TELA Bio has market cap of $27M and EV of $32M.
Equity research analysts estimate TELA Bio's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
TELA Bio has a P/E ratio of (0.7x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $27M | XXX | $27M | XXX | XXX | XXX |
| EV (current) | $32M | XXX | $32M | XXX | XXX | XXX |
| EV/Revenue | 0.4x | XXX | 0.4x | XXX | XXX | XXX |
| EV/EBITDA | (1.1x) | XXX | (1.0x) | XXX | XXX | XXX |
| EV/EBIT | (1.0x) | XXX | (1.0x) | XXX | XXX | XXX |
| EV/Gross Profit | 0.6x | XXX | 0.6x | XXX | XXX | XXX |
| P/E | (0.7x) | XXX | (0.7x) | XXX | XXX | XXX |
| EV/FCF | (1.1x) | XXX | (1.1x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified TELA Bio Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
TELA Bio Margins & Growth Rates
TELA Bio's revenue in the last 12 month grew by 9%.
TELA Bio's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.4M for the same period.
TELA Bio's rule of 40 is (25%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
TELA Bio's rule of X is (13%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
TELA Bio Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 9% | XXX | 8% | XXX | XXX | XXX |
| EBITDA Margin | (37%) | XXX | (38%) | XXX | XXX | XXX |
| EBITDA Growth | (12%) | XXX | (7%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | (25%) | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | (13%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.4M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.4M | XXX | XXX | XXX |
| S&M Expenses to Revenue | 78% | XXX | 79% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 19% | XXX | 20% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 11% | XXX | 11% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 110% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
TELA Bio Public Comps
See public comps and valuation multiples for other Medical Devices comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| IMD International Medical | XXX | XXX | XXX | XXX | XXX | XXX |
| Icecure Medical | XXX | XXX | XXX | XXX | XXX | XXX |
| European Medical Solutions | XXX | XXX | XXX | XXX | XXX | XXX |
| Lifeward | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
TELA Bio M&A Activity
TELA Bio acquired XXX companies to date.
Last acquisition by TELA Bio was on XXXXXXXX, XXXXX. TELA Bio acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by TELA Bio
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialTELA Bio Investment Activity
TELA Bio invested in XXX companies to date.
TELA Bio made its latest investment on XXXXXXXX, XXXXX. TELA Bio invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by TELA Bio
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout TELA Bio
| When was TELA Bio founded? | TELA Bio was founded in 2012. |
| Where is TELA Bio headquartered? | TELA Bio is headquartered in United States. |
| How many employees does TELA Bio have? | As of today, TELA Bio has over 209 employees. |
| Who is the CEO of TELA Bio? | TELA Bio's CEO is Anthony Koblish. |
| Is TELA Bio publicly listed? | Yes, TELA Bio is a public company listed on Nasdaq. |
| What is the stock symbol of TELA Bio? | TELA Bio trades under TELA ticker. |
| When did TELA Bio go public? | TELA Bio went public in 2019. |
| Who are competitors of TELA Bio? | TELA Bio main competitors are Myomo, IMD International Medical, Icecure Medical, European Medical Solutions. |
| What is the current market cap of TELA Bio? | TELA Bio's current market cap is $27M. |
| What is the current revenue of TELA Bio? | TELA Bio's last 12 months revenue is $82M. |
| What is the current revenue growth of TELA Bio? | TELA Bio revenue growth (NTM/LTM) is 9%. |
| What is the current EV/Revenue multiple of TELA Bio? | Current revenue multiple of TELA Bio is 0.4x. |
| Is TELA Bio profitable? | No, TELA Bio is not profitable. |
| What is the current EBITDA of TELA Bio? | TELA Bio has negative EBITDA and is not profitable. |
| What is TELA Bio's EBITDA margin? | TELA Bio's last 12 months EBITDA margin is (37%). |
| What is the current EV/EBITDA multiple of TELA Bio? | Current EBITDA multiple of TELA Bio is (1.1x). |
| What is the current FCF of TELA Bio? | TELA Bio's last 12 months FCF is ($31M). |
| What is TELA Bio's FCF margin? | TELA Bio's last 12 months FCF margin is (37%). |
| What is the current EV/FCF multiple of TELA Bio? | Current FCF multiple of TELA Bio is (1.1x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.